On 26 April Bill Scott wrote: > Okay, Allen, you make me do my homework. > Regarding the issues below, this is from Medscape: Go to one of Thomas AM > Kramer's CME articles at medscape such as: > http://www.medscape.com/viewarticle/420839 > > Then click on "disclosures" at the top of the page. You will find the > following. > > Disclosure: Thomas Kramer, MD, has disclosed that he receives funding for > clinical grants from Pfizer, Eli Lilly, Abbott, and Janssen. He holds > consulting agreements with Pfizer, Eli Lilly, Glaxo, and Wyeth-Ayerst. > > Now I am no longer just highly suspicious that he is well funded by the drug > companies, I "am sure". Still, thanks for making me provide the evidence for > my conjectures.
I checked http://www.medscape.com/viewarticle/420839 and found the article: Antidepressant Response and Noradrenaline Disclosures Thomas Kramer, MD I then clicked �Disclosures� and found the following: 42nd Annual Scientific Meeting of the American Headache Society Clinical Features and Guidelines Faculty and Disclosures Authors Martin L. Korn, MD Private Practice, New York City, NY Disclosure: Martin L. Korn, MD, has disclosed that he has discussed the unlabeled use of topiramate, gabapentin, lamotragine, and carbamazapine in the treatment of bipolar disorder. Peter D. Kramer, MD Clinical Professor, Department of Psychiatry and Human Behavior, Brown University. Disclosure: Thomas Kramer, MD, has disclosed that he receives funding for clinical grants from Pfizer, Eli Lilly, Abbott, and Janssen. He holds consulting agreements with Pfizer, Eli Lilly, Glaxo, and Wyeth-Ayerst. Takuya Saito, MD, PhD Assistant Professor, Department of Psychiatry, Albert Einstein College of Medicine, Bronx, New York. Disclosure: Takuya Saito, MD, has no significant financial interests to disclose. As three Authors are cited, and from the heading, it is evident that the �Disclosures� are for the Meeting as a whole, not specifically for the article �Strategies and Tactics in the Medication Management of Depression� by Thomas Kramer, MD. If you look more closely at the Disclosure list it is evident an error has occurred: Peter D. Kramer, MD Clinical Professor, Department of Psychiatry and Human Behavior, Brown University. Disclosure: Thomas Kramer, MD, has disclosed that he receives funding for clinical grants from Pfizer, Eli Lilly, Abbott, and Janssen. He holds consulting agreements with Pfizer, Eli Lilly, Glaxo, and Wyeth-Ayerst. It would appear that the author for whom the disclosure is being made is Peter D. Kramer, Brown University, not Thomas A. M. Kramer, Northwestern University, Chicago. It looks as if whoever is responsible for preparing the disclosure list may have mistakenly written "Thomas Kramer" in the disclosure statement beneath the name Peter D. Kramer, MD. That "Thomas Kramer" is the likely error (not, the author cited, Peter D. Kramer) is suggested from the previous named author, Martin L. Korn, MD. In the disclosure statement the name Martin L. Korn, MD is repeated in full, unlike in the case of Peter D. Kramer. Evidently the full name of the author is always given in the disclosure statement, whereas in that beneath Peter D. Kramer the shortened name "Thomas Kramer" is given. My guess is that whoever wrote the disclaimer statement for Peter D. Kramer confused the author of the article "Antidepressant Response and Noradrenaline" (Thomas Kramer) with Peter D. Kramer, and wrote the wrong name under the latter�s disclosure information. But I hope all will be revealed after I receive a response from the Medscape site director, to whom I have sent an e-mail asking him to clarify this anomaly. Allen Esterson Former lecturer, Science Department Southwark College, London [EMAIL PROTECTED] http://www.human-nature.com/esterson/index.html http://www.butterfliesandwheels.com/articleprint.php?num=10 --- You are currently subscribed to tips as: [EMAIL PROTECTED] To unsubscribe send a blank email to [EMAIL PROTECTED]
